- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04819347
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
The Phase 2, Two Arms, One Site, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection After Analytical Treatment Interruption
Study Overview
Detailed Description
This is an open-label, one site study, in which a total of 24 HIV-1 subjects who are virologically suppressed and stable on daily oral combination antiretroviral therapy will be enrolled.
All eligible patients will be switched from daily oral combination antiretroviral regimen to treatment of ABT and 3BNC117 for 14 weeks. There is a two-week overlap of the baseline oral antiretroviral therapy and the ABT-3BNC117 combination regimen at the beginning of the study treatment, and then the oral ART will be interrupted.
The patients will be monitored for viral rebound every two or four weeks following initiation of ABT-3BNC117 combination and will re-initiate an oral antiretroviral regimen if virological rebound is confirmed with plasma HIV-1 RNA levels above 200 copies/ml on two consecutive test.
Pharmacokinetics of ABT and 3BNC117 will be assessed in this study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Cheng Yao
- Email: yaocheng@frontierbiotech.com
Study Contact Backup
- Name: Xingxiang Xu
- Phone Number: 025-69648410
- Email: xxxu@frontierbiotech.com
Study Locations
-
-
-
Beijing, China
- Peking Union Medical College Hospital
-
Contact:
- Taisheng Li, M.D.
- Email: litsh@263.net
-
Principal Investigator:
- Taisheng Li, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females, age ≥18 years
For cohort 1: HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), having the document evidence of initial diagnosis of HIV-1 infection and initiation of ART therapy within 6 months of PHI.
For cohort 2: Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), having the document evidence of initial diagnosis of HIV-1 infection and initiation of ART therapy after 6 months of PHI.
- Plasma HIV-1 RNA <50 copies/mL for at least 12 months prior to Screening Visit. An exception for a recorded HIV-1 RNA "blip" (e.g., transient HIV-1 RNA >50 copies/mL) can be considered.
- Plasma HIV-1 RNA <20 copies/mL at Screening Visit.
- CD4 cell count >500 cells/µL.
Laboratory values at Screening of:
- Absolute neutrophil count (ANC) ≥0.75×10∧9/L;
- Hemoglobin (Hb) ≥105 g/L (male) or ≥95 g/L (female);
- Platelets ≥75×10∧9/L;
- Serum alanine transaminase (SGPT/ALT) < 2 x upper limit of normal (ULN)
- Serum aspartate transaminase (SGOT/AST) < 2 x ULN
- Bilirubin (total) <2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease
- Creatinine ≤1.5 x ULN
- Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator.
- Both male and female patients and their partners of childbearing potential must agree to use accepted methods of contraception.
- Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.
- Subjects who have two or more potential alternative antiretroviral treatment regimens.
- Willing and able to participate in all aspects of the study, including use of IV medication, completion of evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.
Exclusion Criteria:
- Any active infection or malignancy requiring acute therapy.
- Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg).
- Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV RNA assay at the time of screening.
- Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
- Unexplained fever or clinically significant illness within 1 week prior to the first study dose
- Any vaccination within 2 weeks prior to the first study dose.
- Subjects BMI<20 or >27 kg/m∧2 [BMI=weight/height∧2].
- History of Bleeding Disorder or patients on anti-coagulant therapy
- Participation in an experimental drug trial(s) within 30 days of the Screening Visit
- Any known allergy or antibodies to the study drug or excipients
Treatment with any of the following:
- Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit
- Receipt of any fusion inhibitor and monoclonal antibody therapy of any kind in the past.
- Immunosuppressants within 60 days prior to the Screening Visit
- Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the screening visit
- Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:
- Subjects on inhaled, nasal, or topical steroids will not be excluded
- Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early treatment of infection
HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months. Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks. |
Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
Other Names:
Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
|
Experimental: Chronic period of infection treatment
Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months. Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks. |
Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
Other Names:
Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants (with sustained viral suppression at week 14) with HIV-1 RNA < 50 copies/mL at Week 26 (24 weeks after ATI)
Time Frame: Week 26
|
Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26.
|
Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean time to virologic rebound (HIV-1 RNA≥200 copies/mL) after ATI
Time Frame: up to 48 weeks
|
Mean time to virologic rebound
|
up to 48 weeks
|
Proportion of participants without experiencing virologic rebound (HIV-1 RNA<200 copies/mL) at Week 26 (24 weeks after ATI).
Time Frame: Week 26
|
Proportion of participants without experiencing virologic rebound
|
Week 26
|
Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26 (24 weeks after ATI).
Time Frame: Week 26
|
Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26
|
Week 26
|
Mean change in CD4 cell count after ATI
Time Frame: up to 48 weeks
|
Mean change in CD4 cell count
|
up to 48 weeks
|
Mean change in CD4/CD8 ration after ATI
Time Frame: up to 48weeks
|
Mean change in CD4/CD8 ration
|
up to 48weeks
|
Frequency of emergence of new resistance mutations after virologic rebound
Time Frame: up to 48 weeks
|
Frequency of emergence of new resistance mutations
|
up to 48 weeks
|
Mean time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound
Time Frame: up to 48 weeks
|
Mean time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound
|
up to 48 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Cheng Yao, Frontier Biotechnologies Inc.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- ABT-3BNC117_202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID); Emory University and other collaboratorsCompletedHIV | AIDSUganda, South Africa
-
University of California, San DiegoCompleted
-
University of California, San DiegoJanssen Research & Development, LLCCompleted
-
Elizabeth Glaser Pediatric AIDS FoundationPopulation Council; Ministry of Health, TanzaniaCompleted
-
Medical College of WisconsinNational Institute of Mental Health (NIMH)CompletedHIV | AIDSUnited States, Russian Federation
Clinical Trials on Albuvirtide
-
Frontier Biotechnologies Inc.Completed
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
Frontier Biotechnologies Inc.Unknown
-
Shanghai Public Health Clinical CenterCompletedDrug InteractionChina
-
Frontier Biotechnologies Inc.Completed